TEAS RF New Application

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number. PTO Form 1478 (Rev 09/2006)

OMB No. 0651-0009 (Exp 02/28/2021)

---

Under the Paperwork Reduction Act of 1995 no persons are required to respond to a collection of information unless it displays a valid OMB control number. PTO Form 1478 (Rev 09/2006)

OMB No. 0651-0009 (Exp 02/28/2021)

Trademark/Service Mark Application, Principal Register

Serial Number: 88327598

Filing Date: 03/06/2019

To the Commissioner for Trademarks:

MARK: PAIGE (Standard Characters, see mark)
The literal element of the mark consists of PAIGE.
The mark consists of standard characters, without claim to any particular font style, size, or color.

The applicant, PAIGE.AI, Inc., a corporation of Delaware, having an address of
      Tata Innovation Center
      11 East Loop Road, Suite 5A
      New York, New York 10044
      United States

requests registration of the trademark/service mark identified above in the United States Patent and Trademark Office on the Principal Register established by the Act of July 5, 1946 (15 U.S.C. Section 1051 et seq.), as amended, for the following:

       International Class 009:  Software, namely, computer programs for artificial intelligence, machine learning, deep learning, statistical learning, data mining, and contextual prediction; software for use in disease pathology, namely, software that reads digital slides and provides diagnoses; software for use in evaluation of prognosis relating to diseases, states, or conditions; software for use in monitoring of diseases, states, or conditions; software for use to detect or identify predispositions to diseases, states, or conditions; software for use to detect or determine the recurrence of diseases, states, or conditions; software for use to detect, monitor, or evaluate patients' responses to treatment of diseases, states, or conditions; software for use in clinical management of diseases, states, or conditions; software for use in the selection of treatment for diseases, states, or conditions; software for use in prevention of diseases, states, or conditions, namely, software that reviews and analyzes clinical pathology slides, and identifies measures to prevent future disease development; software for use in palliation or treatment of diseases, states or conditions; software for use in research or development in the field of life sciences; software for use in research or development in the field of medicine; software for use in research or development in the field of healthcare; software for use in research or development in the field of cancer; software for use in research or development in the field of oncology; software for use in research or development in the field of pathology
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.

       International Class 042:  Software as a service (SaaS) services featuring software for artificial intelligence, machine learning, deep learning, statistical learning, data mining, and contextual prediction; software as a service (SaaS) services featuring software for use in disease pathology, namely, software that reads digital slides and provides diagnoses; software as a service (SaaS) services featuring software for use in diagnosis of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in evaluation of prognosis relating to diseases, states, or conditions; software as a service (SaaS) services featuring software for use in monitoring of diseases, states, or conditions; software as a service (SaaS) services featuring software for use to detect or identify predispositions to diseases, states, or conditions; software as a service (SaaS) services featuring software to detect the recurrence of diseases, states, or conditions; software as a service (SaaS) services featuring software to detect, monitor, or evaluate patients' responses to treatment of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in clinical management of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in the selection of treatment of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in prevention of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in palliation or treatment of diseases, states, or conditions; software as a service (SaaS) services featuring software for use in research or development in the field of life sciences; software as a service (SaaS) services featuring software for use in research or development in the field of medicine; software as a service (SaaS) services featuring software for use in research or development in the field of healthcare; software as a service (SaaS) services featuring software for use in research or development in the field of cancer; software as a service (SaaS) services featuring software for use in research or development in the field of oncology; software as a service (SaaS) services featuring software for use in research or development in the field of pathology; design and development of AI-powered computer software that analyzes clinical pathology slides and diagnoses diseases; medical research; scientific research and development services in the field of pathology; research and development services in the field of medicine; research and development services in the field of cancer; research and development services in the field of healthcare; research and development services in the field of life sciences; research and development services in the field of oncology; medical and scientific research services in the field of pathology; medical and scientific research services in the field of cancer; medical and scientific research services in the field of healthcare; medical and scientific research services in the field of life sciences; medical and scientific research services in the field of oncology; research and development of technology in the field of pathology; research and development of technology in the field of medicine; research and development of technology in the field of cancer; research and development of technology in the field of healthcare; research and development of technology in the field of life sciences; research and development of technology in the field of oncology; providing medical research and scientific research information via the internet; electronic scanning of clinical pathology slides; software as a service services (SaaS) featuring software for use in the analysis of clinical pathology slides; medical and scientific testing services for research purposes
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.

       International Class 044:  Medical services; cancer therapy services; medical testing, namely, the review and analysis of patients' clinical slides to identify additional recommended medical testing; medical testing for the diagnosis of diseases, states, or conditions; medical testing for evaluation of prognosis relating to diseases, states, or conditions; medical testing for the monitoring of diseases, states, or conditions; medical testing to detect or identify predispositions to diseases, states, or conditions; medical testing to detect or determine the recurrence of diseases, states, or conditions; medical testing to detect, monitor, or evaluate responses to treatment of diseases, states, or conditions; medical testing to evaluate clinical management of diseases, states, or conditions; medical testing for selection of treatment for diseases, states, or conditions; medical testing to evaluate or facilitate prevention of diseases, states, or conditions; medical testing to select, facilitate, monitor, or evaluate palliation or treatment of diseases, states or conditions; medical testing in the field of cancer; medical testing in the field of oncology; medical diagnostic testing, monitoring, or reporting services; medical analysis or advisory services in the field of cancer; medical analysis or advisory services in the field of oncology; medical analysis or advisory services for medical treatment; medical analysis or advisory services for the diagnosis of diseases, states, or conditions; medical analysis or advisory services for the evaluation of prognosis relating to diseases, states, or conditions; medical analysis or advisory services relating to monitoring diseases, states, or conditions; medical analysis or advisory services relating to the detection or identification of predispositions to diseases, states, or conditions; medical analysis or advisory services relating to the detection or determination of the recurrence of diseases, states, or conditions; medical analysis or advisory services relating to the detection, monitoring, or evaluation of responses to treatment of diseases, states, or conditions; medical analysis or advisory services relating to the clinical management of diseases, states, or conditions; medical analysis or advisory services relating to the selection of treatment for diseases, states, or conditions; medical analysis or advisory services relating to the prevention of diseases, states, or conditions; medical analysis or advisory services relating to the palliation or treatment of diseases, states or conditions; qualitative image analysis in the field of digital pathology for medical purposes; quantitative image analysis in the field of digital pathology for medical purposes; providing non-research related medical information via the internet; medical analysis services for the diagnosis of cancer by reviewing pathological samples on slides
Intent to Use: The applicant has a bona fide intention, and is entitled, to use the mark in commerce on or in connection with the identified goods/services.


The applicant's current Attorney Information:
      Jason S. Howell and Lindsay B. Allen, Britt L. Anderson, Craig A. Beaker, Stefan B. Blum, Craig C. Bradley, Jared H. Bryant, Ai-Tang I. Chang, L. Omar Cojulun, Sabrina J. Danielson, Colleen M. Ganin, Alexander J.A. Garcia, Daniel J. Glenn, Mark S. Goodrich, Lynne E. Graybeal, Patchen M. Haggerty, John P. Halski, Thomas L. Holt, Kacey Kell, Lisa K. Koenig, Elizabeth A. Kristoferson, Kirstin E. Larson, Winfield B. Martin, Alicia A. Matusheski, Lisa T. Oratz, Scott J. Palmer, Seth H. Reagan, Heidi L. Sachs, Grace Han Stanton, James L. Vana, Fabricio Vayra and Robert G. Woolston of Perkins Coie LLP      1201 Third Avenue, Suite 4900
      Seattle, Washington 98101
      United States
      206-359-8000(phone)
      206-359-9000(fax)
      pctrademarks@perkinscoie.com (authorized)
The attorney docket/reference number is 126772-4000.

The applicant's current Correspondence Information:

Jason S. Howell

Perkins Coie LLP

1201 Third Avenue, Suite 4900

Seattle, Washington 98101

206-359-8000(phone)

206-359-9000(fax)

pctrademarks@perkinscoie.com (authorized) E-mail Authorization: I authorize the USPTO to send e-mail correspondence concerning the application to the applicant, the applicant's attorney, or the applicant's domestic representative at the e-mail address provided in this application. I understand that a valid e-mail address must be maintained and that the applicant or the applicant's attorney must file the relevant subsequent application-related submissions via the Trademark Electronic Application System (TEAS). Failure to do so will result in the loss of TEAS Reduced Fee status and a requirement to submit an additional processing fee of $125 per international class of goods/services.

A fee payment in the amount of $825 has been submitted with the application, representing payment for 3 class(es).

Declaration

	Basis: If the applicant is filing the application based on use in commerce under 15 U.S.C. § 1051(a): The signatory believes that the applicant is the owner of the trademark/service mark sought to be registered; The mark is in use in commerce on or in connection with the goods/services in the application; The specimen(s) shows the mark as used on or in connection with the goods/services in the application; and To the best of the signatory's knowledge and belief, the facts recited in the application are accurate. And/Or If the applicant is filing the application based on an intent to use the mark in commerce under 15 U.S.C. § 1051(b), § 1126(d), and/or § 1126(e): The signatory believes that the applicant is entitled to use the mark in commerce; The applicant has a bona fide intention to use the mark in commerce on or in connection with the goods/services in the application; and To the best of the signatory's knowledge and belief, the facts recited in the application are accurate.
	To the best of the signatory's knowledge and belief, no other persons, except, if applicable, concurrent users, have the right to use the mark in commerce, either in the identical form or in such near resemblance as to be likely, when used on or in connection with the goods/services of such other persons, to cause confusion or mistake, or to deceive.
	To the best of the signatory's knowledge, information, and belief, formed after an inquiry reasonable under the circumstances, the allegations and other factual contentions made above have evidentiary support.
	The signatory being warned that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. § 1001, and that such willful false statements and the like may jeopardize the validity of the application or submission or any registration resulting therefrom, declares that all statements made of his/her own knowledge are true and all statements made on information and belief are believed to be true.

Declaration Signature

Signature: /Leo Grady/   Date: 03/06/2019
Signatory's Name: Leo Grady
Signatory's Position: Chief Executive Officer
Payment Sale Number: 88327598
Payment Accounting Date: 03/06/2019

Serial Number: 88327598
Internet Transmission Date: Wed Mar 06 11:29:26 EST 2019
TEAS Stamp: USPTO/BAS-XXX.XX.XXX.XXX-201903061129262
49394-88327598-6209f551717bb488f43ffa4fd
e468e5869dc383096d01254a4df45dc4856f363f
d-CC-9419-20190306111514034570